No Data
Sichuan kelun pharmaceutical (002422.SZ) pharmaceuticals included in the national medical insurance catalog.
Sichuan Kelun Pharmaceutical (002422.SZ) announced that on November 28, 2024, the National Healthcare Security Administration and the Ministry of Human Resources...
The first domestically produced ADC drug has been fully approved for marketing in China. Kelunbote takes the lead. | Quick announcement
① Sichuan Kelun Pharmaceutical's holding subsidiary Kelun Botai has received domestic approval for the marketing of Lukanasatuzumab. ② This drug is used for the treatment of unresectable locally advanced or metastatic breast cancer and is the first domestically produced ADC to receive full approval for marketing in the country. ③ Two additional new drug applications for Lukanasatuzumab have been accepted by the NMPA.
A-shares afternoon announcement: ningbo jianan electronics is expected to win a bid for a 0.125 billion yuan State Grid procurement project.
GLEHOI November 27th | 1. Ningbo Jianan Electronics: The pre-winning project is the 81st batch of procurement (third bidding procurement of measurement equipment for marketing projects) of State Grid Corporation of China in 2024, with a total bid amount of approximately 0.125 billion yuan, accounting for about 13.72% of the company's audited main business income in 2023. 2. Sichuan Kelun Pharmaceutical: The subsidiary's core product Lutathera (sac-TMT) based on the OptiTROP-Breast01 study for the treatment of second-line and above TNBC has been approved for listing by the China National Medical Products Administration. 3. Ningxia Orient Tantalum Industry: The actual controller is China Minmetals Corporation.
Sichuan Kelun Pharmaceutical: The clinical trial application for the new drug SKB501 by its subsidiary has been approved by the National Medical Products Administration.
On November 25th, Kelun Hui announced that sichuan kelun pharmaceutical, a holding subsidiary of the company, has received approval for the clinical trial application of the innovative drug SKB501 developed by Kelun Botai. SKB501 is a novel ADC drug developed using the OptiDC™ platform technology with independent intellectual property rights, intended for the treatment of advanced solid tumors.
Express News | Sichuan Kelun Pharmaceutical established a big health industry company in Zhejiang with a registered capital of 20 million yuan.
Sichuan Kelun Pharmaceutical (002422.SZ): The subsidiary Kelun Botai has signed an exclusive licensing agreement with the Southwest Medical University Affiliated Hospital for the radiolabeled drug conjugate TBM-001.
On November 20, Gelonghui reported that sichuan kelun pharmaceutical (002422.SZ) stated on the investor interaction platform that its subsidiary Kelun Biotech has signed an exclusive licensing agreement with the hospital affiliated with Southwest Medical University for the radioactive nuclide drug conjugate TBM-001, and has initiated collaborative development of other RDC drugs to meet unmet clinical needs, excluding TBM-001.
No Data
No Data